Literature DB >> 26699379

Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.

Peter P Luk1, Jared D Weston2, Bing Yu3,4, Christina I Selinger1, Rafael Ekmejian5, Timothy J Eviston6, Trina Lum1, Kan Gao6, Michael Boyer4,7, Sandra A O'Toole1,3,4, Jonathan R Clark4,6,7, Ruta Gupta1,4.   

Abstract

BACKGROUND: Accurate diagnosis of salivary duct carcinoma requires a high index of suspicion and clinicopathologic correlation. Hallmark genetic changes that may provide novel therapeutic options are being explored.
METHODS: One hundred ninety salivary gland malignancies at Royal Prince Alfred Hospital (from 1989-2014) were reviewed. Human epidermal growth factor receptor 2 (HER2) and androgen receptor status were determined along with multigene profiling.
RESULTS: Twenty-three salivary duct carcinomas were identified, predominantly in men in their fifth to ninth decades of life. Facial nerve palsy (12%) and cervical lymph node metastases (82%) were present, and 96% received postoperative adjuvant therapy. Histologically, the tumors resembled high-grade invasive and in situ ductal carcinoma of the breast. Micropapillary, papillary, sarcomatoid, oncocytic, and mucinous variants were seen. The tumors showed androgen receptor (70%), HER2 amplification (30%), and HRAS, AKT1, PIK3CA, and NRAS mutations (22%; cumulative). The 5-year disease-free survival was 36%.
CONCLUSION: Salivary duct carcinoma demonstrates a wide histopathologic spectrum. Treatment strategies need to take androgen receptor, HER2 amplification, and PIK3CA mutation into account.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E1838-E1847, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  androgen receptor; human epidermal growth factor receptor 2 (HER2) amplification; salivary duct carcinoma; somatic mutations; survival

Mesh:

Substances:

Year:  2015        PMID: 26699379     DOI: 10.1002/hed.24332

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  26 in total

1.  Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.

Authors:  Justin A Bishop; Jeffrey Gagan; Jeffrey F Krane; Vickie Y Jo
Journal:  Head Neck Pathol       Date:  2020-01-27

2.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

3.  Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion.

Authors:  Lisa M Rooper; Lester D R Thompson; Jeffrey Gagan; Bahram R Oliai; Ilan Weinreb; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2020-07-13

4.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

Review 5.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

6.  Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.

Authors:  Marlen Haderlein; Claudia Scherl; Sabine Semrau; Sebastian Lettmaier; Markus Hecht; Ramona Erber; Heinrich Iro; Rainer Fietkau; Abbas Agaimy
Journal:  Strahlenther Onkol       Date:  2017-08-21       Impact factor: 3.621

Review 7.  Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Authors:  Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta
Journal:  Head Neck Pathol       Date:  2018-11-22

8.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

9.  Molecular patterns in salivary duct carcinoma identify prognostic subgroups.

Authors:  Ruta Gupta; Mark J Cowley; Simon A Mueller; Marie-Emilie A Gauthier; James Blackburn; John P Grady; Spiridoula Kraitsek; Elektra Hajdu; Matthias S Dettmer; Jane E Dahlstrom; C Soon Lee; Peter P Luk; Bing Yu; Roland Giger; Sarah Kummerfeld; Jonathan R Clark
Journal:  Mod Pathol       Date:  2020-05-26       Impact factor: 7.842

10.  Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.

Authors:  Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-21       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.